Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 4:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC) Clear all
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
ZEN003694, Enzalutamide
Drug
Lead sponsor
Zenith Epigenetics
Industry
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced May 22, 2026, 4:16 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabozantinib
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 22, 2026, 4:16 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer, Metastatic (Spread to Other Areas of the Body)
Interventions
BKM120
Drug
Lead sponsor
Andrew J. Armstrong, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Durham, North Carolina • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced May 22, 2026, 4:16 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Bevacizumab, Lenalidomide, Docetaxel, Prednisone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced May 22, 2026, 4:16 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radium-223, Sipuleucel-T
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced May 22, 2026, 4:16 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Progressive Metastatic Castrate Resistant Prostate Cancer
Interventions
Tulmimetostat DL1 QD, Tulmimetostat DL2 QD, Tulmimetostat DL3 QD, Tulmimetostat Doses 1 or 2 QD, Tulmimetostat RP2D QD, JSB462 Dose 1 QD, JSB462 Dose 2 QD, JSB462 QD, Standard of Care (SoC)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
5
States / cities
Denver, Colorado • Jacksonville, Florida • Wichita, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 22, 2026, 4:16 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
ARV-766 Part A&B, ARV-766 + Abiraterone Part C&D
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Duarte, California • Fresno, California • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 22, 2026, 4:16 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer
Interventions
Avelumab
Drug
Lead sponsor
Andrew J. Armstrong, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced May 22, 2026, 4:16 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
PF-06821497, Placebo, Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
44
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 22, 2026, 4:16 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer
Interventions
Selinexor
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced May 22, 2026, 4:16 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Bavdegalutamide, Abiraterone
Drug
Lead sponsor
Arvinas Androgen Receptor, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
9
States / cities
Santa Monica, California • New Haven, Connecticut • Fort Myers, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced May 22, 2026, 4:16 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
Interventions
Mervometostat (PF-06821497), Enzalutamide, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
45
States / cities
Tucson, Arizona • Anaheim, California • Duarte, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 22, 2026, 4:16 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Castration-Resistant Prostatic Cancer, Metastasis
Interventions
Docetaxel, Ifinatamab Deruxtecan, MK-5684, Abiraterone, Enzalutamide, Rescue Medication
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 22, 2026, 4:16 AM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
ARV-110
Drug
Lead sponsor
Arvinas Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
54
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced May 22, 2026, 4:16 AM EDT
Terminated Phase 3 Interventional
View directory record Official record
Conditions
Castrate-Resistant Prostate Cancer, Hormone Refractory Prostate Cancer
Interventions
custirsen sodium, isotonic, 0.9% sodium chloride, docetaxel, cabazitaxel, prednisone
Drug
Lead sponsor
Achieve Life Sciences
Industry
Eligibility
18 Years to 99 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
20
States / cities
La Verne, California • Fort Lauderdale, Florida • Tampa, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced May 22, 2026, 4:16 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
Sipuleucel-T Injection
Drug
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
31
States / cities
Tuscon, Arizona • Duarte, California • Fresno, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced May 22, 2026, 4:16 AM EDT
Recruiting Phase 4 Interventional
View directory record Official record
Conditions
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Carcinoma
Interventions
18F-DCFPyl
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced May 22, 2026, 4:16 AM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
[Lu-177]-PNT2002, Abiraterone, Enzalutamide
Drug
Lead sponsor
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
33
States / cities
Tucson, Arizona • Los Angeles, California • Newport Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced May 22, 2026, 4:16 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Castrate Resistent Prostate Cancer
Interventions
BPX-201 vaccine plus AP1903
Biological
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Birmingham, Alabama • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced May 22, 2026, 4:16 AM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumors, CRPC, mCRPC, Metastatic Castrate-resistant Prostate Cancer, PT-112, Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site
Interventions
PT-112 Injection
Drug
Lead sponsor
Promontory Therapeutics Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
17
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced May 22, 2026, 4:16 AM EDT
Withdrawn Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms
Interventions
NUV-422, Enzalutamide
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Canton, Ohio • Gettysburg, Pennsylvania • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced May 22, 2026, 4:16 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Enzalutamide, Venetoclax
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced May 22, 2026, 4:16 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer
Interventions
Dovitinib, Abiraterone Acetate, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced May 22, 2026, 4:16 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer
Interventions
177Lu-PSMA-617, Best supportive/best standard of care
Drug · Other
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Male only
Enrollment
861 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
45
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced May 22, 2026, 4:16 AM EDT